Education
About Us
Working with TipRanks
Follow Us
Vext Science (TSE:VEXT)
:VEXT
Top Page
Vext Science
(OTC:VEXT)
51Neutral
Vext Science (VEXT) vs. S&P 500 (SPY)
Market Cap
$27.23M
Dividend YieldN/A
Average Volume (3M)152.92K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth5.05%
EPS Growth-469.50%
CountryCA
Employees173
SectorHealthcare
Sector Strength39
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.04
Shares Outstanding180,306,050
10 Day Avg. Volume242,551
30 Day Avg. Volume152,924
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.00
P/FCF Ratio13.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.50Price Target Upside356.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Vext Science Business Overview & Revenue Model
Company DescriptionVext Science is a cannabis operator based in the United States, primarily engaged in the cultivation, production, and retailing of cannabis products. The company operates in the healthcare and retail sectors, offering a diverse range of cannabis-related products, including dried flower, edibles, and concentrates. Vext Science focuses on delivering high-quality cannabis products through its owned facilities and retail locations, catering to both medical and recreational cannabis markets.
How the Company Makes MoneyVext Science generates revenue through the cultivation and sale of cannabis products in states where cannabis is legal. The company's key revenue streams include wholesale distribution to dispensaries and direct sales through its own retail outlets. Vext Science benefits from vertical integration, owning and operating cultivation facilities, production sites, and retail dispensaries, which allows them to capture value at multiple points in the supply chain. Additionally, the company may engage in strategic partnerships or licensing deals to expand its product offerings and market reach, contributing to its overall earnings.
Vext Science Financial Statement Overview
Summary
Vext Science is facing significant profitability and cash flow challenges despite a stable asset base. The company has transitioned from profitability to a net loss, with inconsistent revenue growth indicating operational inefficiencies and market pressures. The balance sheet remains reasonably leveraged, but improving cash flow generation is crucial for financial health.Income Statement
Vext Science's revenue growth has been inconsistent with a recent decline, while gross profit margin has decreased over the years, indicating rising costs or pricing pressures. Notably, the company swung from positive net income in 2023 to a significant net loss in 2024, reflecting challenges in profitability. The negative EBIT and EBITDA margins in 2024 further highlight operational inefficiencies, negatively impacting the income statement score.40
Negative
Balance Sheet
The balance sheet shows a moderate debt-to-equity ratio due to increasing total debt, but the equity base remains strong. Return on equity has turned negative with recent net losses, presenting a concern. However, the equity ratio is relatively healthy, suggesting reasonable financial leverage and a stable asset base.60
Neutral
Cash Flow
Recent negative free cash flow growth, coupled with declining operating cash flow, raises concerns about cash generation capabilities. However, the operating cash flow to net income ratio remains positive, indicating some level of operational efficiency. The cash flow statement reflects potential liquidity challenges if current trends persist.55
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 36.00M | 34.81M | 35.41M | 37.24M | 25.19M | Gross Profit |
| 8.98M | 12.04M | 23.10M | 18.69M | 11.20M | EBIT |
| -11.18M | -1.80M | 8.93M | 9.49M | 3.22M | EBITDA |
| -2.02M | 16.77M | 15.03M | 12.80M | 5.52M | Net Income Common Stockholders |
| -22.44M | 4.40M | 10.92M | 4.99M | 2.13M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 4.62M | 8.72M | 5.93M | 6.47M | 1.75M | Total Assets |
| 136.97M | 149.56M | 120.52M | 83.70M | 55.45M | Total Debt |
| 39.52M | 38.60M | 38.15M | 14.10M | 11.49M | Net Debt |
| 34.89M | 29.88M | 32.22M | 7.64M | 9.74M | Total Liabilities |
| 61.23M | 54.58M | 48.60M | 24.31M | 19.14M | Stockholders Equity |
| 75.74M | 94.98M | 71.92M | 59.39M | 36.31M |
| Cash Flow | Free Cash Flow | |||
| 1.82M | 1.69M | -2.94M | -7.10M | -964.90K | Operating Cash Flow |
| 3.29M | 4.42M | 5.92M | 11.68M | 3.10M | Investing Cash Flow |
| -5.44M | -4.82M | -30.31M | -27.10M | -12.90M | Financing Cash Flow |
| -1.95M | 3.19M | 23.86M | 20.14M | 4.26M |
Vext Science Technical Analysis
Negative
0.11
Price Trends
0.15
Negative
0.15
Negative
0.18
Negative
Market Momentum
-0.01
Positive
38.01
Neutral
27.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Negative. The current price of 0.11 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.15, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 38.01 is Neutral, neither overbought nor oversold. The STOCH value of 27.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VEXT.
Vext Science Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $22.99M | ― | -6.91% | ― | 21.39% | -39.94% | |
58 Neutral | $37.50M | 3.76 | 23.19% | ― | -20.20% | ― | |
52 Neutral | $5.14B | 3.39 | -43.55% | 2.83% | 16.49% | -0.19% | |
51 Neutral | $27.23M | ― | -26.28% | ― | 5.05% | -469.50% | |
50 Neutral | $39.44M | ― | -16.22% | ― | 26.92% | 27.22% | |
49 Neutral | C$24.61M | ― | -13.58% | ― | 0.96% | -32.11% | |
44 Neutral | C$24.99M | ― | -31.24% | ― | 44.21% | 21.93% |
* Healthcare Sector Average
Performance Comparison
TSE:VEXT
Vext Science
0.11
-0.21
-65.63%
TSE:LABS
MediPharm Labs
0.10
0.03
33.33%
TSE:DB
Decibel Cannabis Company
0.07
-0.05
-43.48%
TSE:ROMJ
Rubicon Organics
0.41
0.02
6.49%
TSE:CXXI
C21 Investments
0.21
-0.32
-60.38%
TSE:GWAY
Greenway Greenhouse Cannabis Corp.
0.19
-0.11
-36.67%
Vext Science Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q4-2024)
| % Change Since: -37.14%|
Next Earnings Date:May 21, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong performance in Ohio with significant revenue growth and record adjusted EBITDA, which helped offset challenges faced in the Arizona market. While Vext experienced some non-cash impairment charges and increased inventory investments, the company's ability to generate positive cash flow and its strategic expansion in Ohio were positive indicators.Q4-2024 Updates
Positive Updates
Strong Performance in Ohio
The fourth quarter of 2024 was the first full quarter of adult-use sales in Ohio, resulting in revenue growth of $10.2 million and adjusted EBITDA of $3.2 million. Ohio operations demonstrated significant growth with a 40% increase in total sales in Q4 2024.
Record Adjusted EBITDA
Vext achieved the highest quarterly adjusted EBITDA in more than two years, with a 13% increase sequentially to $3.2 million in Q4 2024. For the full year, adjusted EBITDA increased by 66% to $9.2 million compared to fiscal 2023.
Positive Cash Flow from Operations
The fourth quarter of 2024 marked the highest quarterly cash flow from operations in three years, at $4 million. Cash flow from operations for the full year was $3.3 million, despite a 24% decline compared to fiscal 2023.
Expansion in Ohio
Vext is on track to reach Ohio's license cap of eight stores, with new locations set to open throughout 2025 and potentially into early 2026. The acquisition of two dispensaries is nearing completion, with expected significant revenue and profitability growth from the state.
Negative Updates
Challenges in Arizona Market
Arizona experienced a 12.6% decline in total statewide sales, with average per store sales declining by 25%. Vext faced pricing pressure due to oversupply and heightened competition, although it managed to increase retail sales by 2.4%.
Non-Cash Impairment Charge
Vext recorded a non-cash impairment charge of $2.9 million in Q4 2024 due to winding down joint ventures in Oklahoma and California, attributed to market challenges and oversupply.
Increased Inventory Investments
While Vext's cash flow from operations was positive, it represented a decline due to increased inventory investments to support elevated adult-use demand in Ohio.
Company Guidance
During the Vext Science Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call, the company reported several key metrics highlighting its performance and future outlook. For fiscal year 2024, Vext generated $36 million in revenue, marking a 3% increase compared to the previous year, with adjusted EBITDA rising by 66% to $9.2 million. In the fourth quarter alone, revenue reached $10.2 million, a sequential increase of 13%, driven by strong adult-use sales in Ohio. The Ohio market contributed significantly with a 33% increase in third-party wholesale sales from Q3 to Q4. The company emphasized its vertically integrated model, which has allowed Vext to generate strong operating cash flow of $4 million in Q4, the highest in three years, and maintain a solid balance sheet with $4.6 million in cash. Looking ahead, Vext anticipates further growth from Ohio, with plans to reach the state's license cap of eight retail locations by early 2026, while also focusing on optimizing operations in Arizona despite market challenges. The company also aims to eliminate all non-mortgage debt by the end of 2026.Vext Science Corporate Events
Financial Disclosures
Vext Science to Release Q1 2025 Financial Results on May 21
Neutral
May 13, 2025
Vext Science, Inc. announced it will release its Q1 2025 financial results on May 21, 2025, before the market opens. The company will also host a conference call and webcast to discuss these results, reflecting its continued focus on growth and stakeholder engagement in its core markets of Arizona and Ohio.
The most recent analyst rating on (TSE:VEXT) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Vext Science stock, see the TSE:VEXT Stock Forecast page.
Spark’s Take on TSE:VEXT Stock
According to Spark, TipRanks’ AI Analyst, TSE:VEXT is a Neutral.
Vext Science’s overall score reflects significant challenges in financial performance, with profitability and cash flow issues weighing heavily. While the company shows potential with strategic expansions in Ohio and positive earnings call highlights, weak technical indicators and poor valuation metrics limit the stock’s attractiveness. Continued focus on operational efficiency and cash flow generation will be key to improving its financial health.
To see Spark’s full report on TSE:VEXT stock, click here.
M&A TransactionsBusiness Operations and Strategy
Vext Science Sells Kentucky License to Focus on Core Markets
Positive
Apr 4, 2025
Vext Science, Inc. has announced the sale of its medical cannabis processing license in Kentucky for $880,000, as part of a strategic move to concentrate on its core markets in Arizona and Ohio. The transaction is expected to bolster Vext’s balance sheet, aiding in the expansion of its retail operations in Ohio and supporting general corporate purposes. This decision reflects Vext’s disciplined capital allocation strategy and commitment to maximizing returns in its primary operational areas.
M&A TransactionsBusiness Operations and Strategy
Vext Science Expands Ohio Cannabis Retail Operations
Positive
Apr 3, 2025
Vext Science, Inc. has expanded its retail presence in Ohio by acquiring two additional cannabis dispensaries, bringing its total to four in the state. This strategic move is part of Vext’s plan to reach the state license cap of eight dispensaries by early 2026, enhancing its distribution control and aligning with its cultivation and manufacturing assets. The expansion is expected to generate consistent cash flow and create long-term value for shareholders, with further growth anticipated in 2025 and beyond.
Business Operations and StrategyFinancial Disclosures
Vext Science Reports Strong Q4 2024 Results and Expands Ohio Operations
Positive
Mar 31, 2025
Vext Science reported a strong Q4 2024, marked by significant growth in revenue, adjusted EBITDA, and cash flow, driven by the expansion of Ohio’s adult-use market and operational efficiency in Arizona. The company secured regulatory approval to acquire additional dispensaries in Ohio, positioning itself to double its retail footprint in the state by early 2026. This strategic expansion is expected to enhance Vext’s market share and profitability, as it continues to focus on driving free cash flow and maximizing shareholder value.
Financial Disclosures
Vext Science to Release Q4 and Fiscal 2024 Financial Results on March 31, 2025
Neutral
Mar 19, 2025
Vext Science, Inc. announced that it will release its financial results for the fourth quarter and fiscal year 2024 on March 31, 2025. The company will also host a conference call and webcast to discuss these results. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor confidence.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.